BRAF: which options do we have for these patients in second line?

21 / 22

CONCLUSIONS
• BRAF mutant CRC have a particular biology but is a complex entity and a heterogenous
disease. Drug combinations offering benefit have an added value.
• Testing for BRAF mutation is standard of care in mCRC:
• Strong prognostic factor: Useful to define treatment strategies
• Predictive value not demonstrated yet, but the available evidence is enough to
state that these tumors do not obtain benefit from anti-EGFR therapies
• BRAF mutant patients have options in second line.
• When focusing on 2nd line-SOC: FOLFIRI-aflibercept has consistent efficacy benefit
across all patient types including BRAF mutant patient being the only antiangiogenic
drug offering data in this poor prognosis population.